BioSpace News Archive

Cingulate Inc. today announced that Shane J. Schaffer, Chairman and Chief Executive Officer, will present a company overview at the Aegis Capital Corp. Virtual Conference on February 24, 2022, at 10:30 a.m. ET.

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the appointment of Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as Chief Legal Officer and Corporate Secretary.

Basilea Pharmaceutica Ltd., a commercial-stage biopharmaceutical company, announced its results for the financial year ended December 31, 2021, and strategic decisions to optimize the long-term value of its two business pillars, anti-infectives and oncology.

AffaMed Therapeutics announced that the United States Food and Drug Administration has cleared its Investigational New Drug application for the clinical development of AM712, a novel proprietary bispecific biologic molecule blocking both vascular endothelial growth factor and angiopoietin-2 for the treatment of retinal vascular diseases.

Genuv, Inc. announced an agreement with the medical technology company Aiforia Technologies Plc, to add Aiforia’s AI deep learning for medical image analysis to its ATRIVIEW® discovery platform.

PureTech Health plc announced that Social Capital Suvretta Holdings Corp. I has filed with the U.S. Securities and Exchange Commission a registration statement on Form S-4, which contains a preliminary proxy statement/prospectus, in connection with the previously announced proposed business combination with Akili.

Topas Therapeutics GmbH, a private biotechnology company developing immune tolerance-inducing drugs to treat and potentially cure a variety of autoimmune diseases, announced the appointment of Cristina de Min, M.D., as Chief Medical Officer.

Poster on Interim Trial Data Comparing MRI-Guided vs. CT-Guided SBRT Toxicities for Prostate Cancer to be Featured at American Society of Clinical Oncology GU Cancers Symposium.

NMD Pharma A/S, a clinical stage biotech company developing first in class, small molecule CLC-1 inhibitors for neuromuscular disorders, announces that it has raised €35 million in a new financing.

ArriVent Biopharma, Inc., industry leaders dedicated to accelerating the global development of innovative biopharmaceutical products, today announced the appointment of Bahija Jallal, Ph.D. to its Board of Directors.